Cerba and Taliaz to Leverage Artificial Intelligence and Genetic Expertise to Improve Care Management for Depression Patients

Cerba and Taliaz to Leverage Artificial Intelligence and Genetic Expertise to Improve Care Management for Depression Patients

SAINT OUEN L’AUMÔNE, France & TEL AVIV, Israel–(BUSINESS WIRE)–Cerba, the leading reference in specialty clinical pathology, and Taliaz, an Israeli digital health company dedicated to improving mental health disorders, today announced a partnership to providing physicians with an AI-based precision psychiatry solution that predicts depression treatment efficacy. By finding the right treatment from the very first prescription, the test helps doctors make the best treatment decision for their patients faster and can speed up the recovery of the 280 million people worldwide who suffer from depression..

Today, 5% of the world’s adult population suffers from depression, one of the most common mental health disorders, according to the World Health Organization (1). The correct medical prescription of antidepressant compounds has become a critical issue in patient care because lack of response or remission occurs in 20–30% of patients with a severe depressive episode (2). In France alone, 1 person out of 4 suffers from mental disorders and 1 person out of 5 suffers from depression.

To meet this challenge, Cerba and Taliaz are joining forces to offer clinicians a new predictive clinical test of the effectiveness of antidepressant treatments: PREDICTIX, developed by Taliaz, is based on a biological test coupled with artificial intelligence to guide the management of depressed patients by presenting the drug with the best chance of therapeutic success the first time. Designed as a clinical decision support tool, the solution takes precision AI-powered psychiatry to the next level and is expected to improve care for millions of patients worldwide. It should be available to patients by January 2023 throughout the Cerba HealthCare routine clinical pathology network in France and abroad.

The PREDICTIX test uses AI to analyze multiple streams of patient data, including genetic, metabolic, demographic, and clinical information. Physicians receive a personalized patient report that predicts and ranks the statistical effectiveness, dosage, and potential side effects of various antidepressant medications based on each patient’s pharmacogenetic makeup and medical history. Clinical research has demonstrated a 72.2% response rate and real-world data has shown that 90% of patients experienced clinical improvement after 8 weeks on the Clinical Global Impressions (CGI) scale, a useful tool for clinicians and patients used in clinical practice (3) .

Jérôme Sallette, scientific director of Cerba HealthCare comments: With the introduction of PREDICTIX, we are entering a new era of precision medicine in psychiatry: empowering physicians to make the best treatment decision faster and reducing the burden of depression on patients and healthcare systems. Cerba is once again at the forefront of innovation to inform diagnosis, improve patient health care and facilitate the right prescription at the right time for the right patient.

Dekel Taliaz, CEO and co-founder of Taliazsaid, “We are delighted to sign this historic agreement with Cerba HealthCare to advance our mental health technology. Their scientific culture and extensive network will expand PREDICTIX’s market entry to a global reach. By leveraging the power of big data and AI in easy-to-use, time-saving clinician tools, we are committed to providing safe and effective solutions to speed recovery and reduce suffering for patients with disease. mind all over the world.

Download the press release

1 World Health Organization, https://www.who.int/en/news-room/fact-sheets/detail/depression, September 2021

2 National Institute of Mental Health, Sequenced Treatment Alternatives for Alleviating Depression (STAR*D) Study

3 Saudreau, B., you in the. (2022). Impact of personalized antidepressant prescription using genetic, sociodemographic and clinical data in patients with major depressive disorder: a clinical pilot study. Pharmacology and pharmacogenomics, 122(1), 122–130. https://doi.org/10.31488/jpp.105

#Cerba #Taliaz #Leverage #Artificial #Intelligence #Genetic #Expertise #Improve #Care #Management #Depression #Patients

Leave a Comment

Your email address will not be published. Required fields are marked *